Latest: FDA Approves New Biosimilar for Oncology Treatment

Balancing Cost, Coverage, and Clinical Value in First-Line Multiple Myeloma Care: Emilie Aschenbrenner, PharmD, BCOP

18 August, 2025

0 Mins

Emilie Aschenbrenner, PharmD, BCOP, discusses how integrating CD38-targeted therapies into first-line treatment for transplant-ineligible multiple myeloma requires balancing clinical benefit, cost, and insurance coverage.

Tags:

Author

American Journal Managed Care

Women Reporting High HIV Stigma Had Higher Odds of Reduced Treatment Adherence

2 Minute Medicine: Pharma Roundup – Landmark lung approval, billion-dollar obesity drug deal, oncology safety halt, and GSK’s China push [August 14 2025]

📢

300x250 Banner

Balancing Cost, Coverage, and Clinical Value in First-Line Multiple Myeloma Care: Emilie Aschenbrenner, PharmD, BCOP

Tags:

American Journal Managed Care

Women Reporting High HIV Stigma Had Higher Odds of Reduced Treatment Adherence

2 Minute Medicine: Pharma Roundup – Landmark lung approval, billion-dollar obesity drug deal, oncology safety halt, and GSK’s China push [August 14 2025]

Recent Content

COPD Biologics: Early Treatment Insights

Antihypertensive Medication Guidelines

Juvenile Arthritis Care Transition